Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.59 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.52 |
| ▸ | ITGB8 | P26012 | 5/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22029493 | 0.91 | ITGAV (0.54) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL22029440 | 0.90 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL29482189 | 0.86 | ITGAV (0.71) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL22029489 | 0.81 | ITGAV (0.64) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL22029467 | 0.81 | ITGAV (0.72) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL24872286 | 0.80 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL22029437 | 0.78 | ITGAV (0.69) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL19825653 | 0.78 | ITGAV (0.62) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL18104630 | 0.78 | ITGAV (0.62) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL21705490 | 0.77 | ITGAV (0.71) | ITGAVITGB3ITGB6ITGB8ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481814-B1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | UNIV ROCKEFELLER (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11192889-B2 | Tetrahydronaphthyridinepentanamide integrin antagonists | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200181138-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181138-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | ITGAV, ITGB3, ITGA4 | ITGAV 1/4885ITGB3 2/4885ITGB6 21/4885 |
| US-11192889-B2 | Tetrahydronaphthyridinepentanamide integrin antagonists | ITGAV, ITGB3, ITGA4 | ITGAV 1/4885ITGB3 2/4885ITGB6 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.